entertainment -WSS

entertainment

author：leisure time 2025-10-01 12:33:51 - browse：9

George Yancopoulos on the 2024 Breakthrough Summit East stage. — George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

George Yancopoulos is in touch with his teenage self.

After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

“My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： How to pay for weight loss drugs and save Medicare

WSS

Diagnostic tests are hitting their mathematical limits

FDA investigates CAR

How I ended up pumping milk in a bathroom stall at JPM 2024

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Risky weight loss products often used by teens globally, per study

Will the market for weight loss drugs really reach $100 billion?

entertainment

entertainment

hotspot

Supreme Court strikes down use of affirmative action

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Malaria cases in Florida and Texas: Here’s what you need to know

U.K. Biobank has 500,000 peoples' genome sequences available

How to save PrEP access — and even expand it

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

United colonoscopy coverage change 'may cost lives,' doctors say

Will the market for weight loss drugs really reach $100 billion?

Virginia high school admissions case could be legal follow

30 years of 'Listening to Prozac'

hotspot

Flagship Pioneering launches a new biotech in two countries

Heart disease and mental health: A look at cardiac psychology

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

As biotech industry slumps, bioscience job market is upside down

Health and fitness trackers are measuring the wrong things

As JPM 2024 winds down, some health tech firms project optimism

Wikipedia

explore

hotspot

focus